| Catalog Number | I027325 |
| CAS Number | 84475-07-0 |
| Synonyms | Fce 22250; Fce-22250; Fce22250
|
| Molecular Formula | C44H58N4O12 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,26E)-2,15,17,29-Tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23,27-trioxo-26-{[(2E)-2-(1-piperidinylmethylene)hydrazino]methylene}-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(28),2,4,9,19,21,25(29)-heptaen-13-yl acetate |
| InChI | InChI=1S/C44H58N4O12/c1-22-14-13-15-23(2)43(56)47-34-29(20-45-46-21-48-17-11-10-12-18-48)38(53)31-32(39(34)54)37(52)27(6)41-33(31)42(55)44(8,60-41)58-19-16-30(57-9)24(3)40(59-28(7)49)26(5)36(51)25(4)35(22)50/h13-16,19-22,24-26,30,35-36,40,45,50-52,54H,10-12,17-18H2,1-9H3,(H,47,56)/b14-13+,19-16+,23-15+,29-20+,46-21+/t22-,24+,25+,26+,30-,35-,36+,40+,44-/m0/s1 |
| InChIKey | SRGITGUCGGVOQM-YNQXYWRISA-N |
| SMILES | CC(O[C@@H]([C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(C)/C(NC(/C1=C/N/N=C/N2CCCCC2)=C3O)=O)[C@H](C)[C@@H](OC)/C=C/O[C@](O4)(C)C(C5=C4C(C)=C(O)C3=C5C1=O)=O)=O |
| Reference | 1: Della Bruna C, Ungheri D, Sebben G, Sanfilippo A. Laboratory evaluation of a new long-acting 3-azinomethylrifamycin FCE 22250. J Antibiot (Tokyo). 1985 Jun;38(6):779-86. PubMed PMID: 3839503.
2: Ungheri D, Morvillo E, Sanfilippo A. [Activity of the ansamycins LM 427 and FCE 22250 on atypical mycobacteria in vitro]. G Ital Chemioter. 1983 May-Dec;30(2-3):97-100. Italian. PubMed PMID: 6329872.
3: Zanetti S, Ungheri D, Castellani Pastoris M, Fadda G. Comparative in vitro susceptibility studies of FCE 22250 and rifampicin on Legionella and Chlamydia trachomatis strains. Drugs Exp Clin Res. 1987;13(10):631-4. PubMed PMID: 3428127.
4: Amitani R, Kuze F. [New drugs against tuberculosis and nontuberculous mycobacterial infections: a review]. Kekkaku. 1994 Nov;69(11):711-7. Review. Japanese. PubMed PMID: 7837725.
5: Abeck D, Johnson AP, Alexander F, Korting HC, Ballard RC. In vitro activity of eight antimicrobial agents against non-penicillinase-producing gonococci isolated in Munich. Genitourin Med. 1988 Aug;64(4):233-4. PubMed PMID: 3139546; PubMed Central PMCID: PMC1194222.
6: Dickinson JM, Mitchison DA. In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle. 1987 Sep;68(3):183-93. PubMed PMID: 2834843.
7: Abeck D, Johnson AP, Dangor Y, Ballard RC. Antibiotic susceptibilities and plasmid profiles of Haemophilus ducreyi isolates from southern Africa. J Antimicrob Chemother. 1988 Oct;22(4):437-44. PubMed PMID: 3264554.
8: Kawahara S. [Chemotherapeutic agents under study]. Nihon Rinsho. 1998 Dec;56(12):3096-9. Review. Japanese. PubMed PMID: 9883617.
9: Vigevani A, Arlandini E, Ballabio M, Franceschi G, Gioia B, Vioglio S. Physico-chemical properties of FCE 22250, 3-(piperidinomethylazinomethyl)rifamycin SV, a new long-acting rifamycin. Farmaco Prat. 1985 May;40(5):131-40. PubMed PMID: 3839192.
10: Liu L, Wang ZY, Li D, Sun SL. [Disposition of 3-(N-piperidinomethylarino)methyl-rifamycin SV (FCE 22250) in rats]. Zhongguo Yao Li Xue Bao. 1991 Jan;12(1):58-62. Chinese. PubMed PMID: 1950587.
|
